Positrigo NeuroPET compact brain PET scanner advances toward clinical deployment — Alzheimer's imaging accessible in neurology clinics
Summary
Swiss startup Positrigo made progress with their NeuroPET compact brain-dedicated PET scanner for Alzheimer's amyloid and tau imaging in 2026, highlighted in the April Neurotech Notables. The device aims to bring amyloid PET out of $2-3M academic PET centers and into standard neurology practices, at a fraction of the infrastructure cost and without requiring a cyclotron on-site. Clinical deployment preparation is underway as lecanemab and donanemab adoption creates urgent demand for accessible amyloid imaging.
Why it matters
Positrigo's timing is perfect: FDA approvals of lecanemab and donanemab create massive demand for amyloid PET as a patient selection and monitoring tool, but current PET infrastructure cannot scale to meet this demand. A room-installable brain PET scanner costing 80-90% less than conventional PET would make Alzheimer's biomarker imaging routinely accessible — the missing link between disease-modifying drug availability and patient access.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial